The first event of the year for PSI Pharmaceutical Statistics Journal Club was a joint event with the RSS. The event, sponsored by Wiley and Quintiles, was on adaptive designs and two papers published in Series C of the RSS journal, and Pharmaceutical Statistics, respectively, were presented. The event took place on May 21st. Speakers Dr Yin, and Dr König presented their work, with Robert Cuffe chairing the Q&A session. Take the opportunity to catch up on the event or even watch again.
Speaker: Guosheng Yin, Department of Statistics and Actuarial Science, University of Hong Kong Two stage adaptive randomisation for delayed response in clinical trials Co-author: Jiajing Xu;
Journal of the Royal Statistical Society: Series C (Applied Statistics), Volume 63, Issue 4, Pages 559–578, August 2014 Links: Abstract | Article full text** | Slides+
Speaker: Franz König, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna Adaptive graph-based multiple testing procedures Co-authors: Florian Klinglmueller, Martin Posch;
Pharmaceutical Statistics, Volume 13, Issue 6, Pages 345–356, November/December 2014 Links: Abstract | Article full text** | Slides+
+ Please note presentation slides available to download from 19th May 2015 ** Available to view from 14th May 2015 to 11th June 2015
For a flier advertising the event please click here.
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.